What Receptor Does Nivolumab Target?
Nivolumab targets the programmed cell death protein 1 (PD-1) receptor on T cells. It binds to PD-1, blocking its interaction with PD-L1 and PD-L2 ligands, which prevents T-cell exhaustion and boosts anti-tumor immune responses.
How Does This Mechanism Enhance Immunity?
PD-1 is an immune checkpoint that downregulates T-cell activity to avoid autoimmunity. Cancer cells exploit this by upregulating PD-L1 to suppress T cells. Nivolumab's blockade restores T-cell proliferation, cytokine production, and tumor cell killing, enhancing adaptive immunity against tumors.
Which Cancers Is Nivolumab Approved For?
FDA approvals cover melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer (MSI-H/dMMR), hepatocellular carcinoma, esophageal cancer, gastric cancer, and mesothelioma, often in combination with ipilimumab or chemotherapy.
Common Side Effects from PD-1 Blockade
Immune-related adverse events occur due to overactive immunity, including fatigue, rash, pruritus, diarrhea, nausea, and severe cases like colitis, pneumonitis, hepatitis, endocrinopathies (thyroiditis, hypophysitis), and myocarditis. Management involves corticosteroids or immunosuppressants.
How Does Nivolumab Compare to Other PD-1 Inhibitors?
| Drug | Brand | Key Differences |
|------|--------|-----------------|
| Nivolumab | Opdivo | Human IgG4 monoclonal antibody; dosed every 2-4 weeks IV; Bristol Myers Squibb. |
| Pembrolizumab | Keytruda | Humanized IgG4; every 3-6 weeks IV; Merck; broader first-line approvals in some cancers. |
| Cemiplimab | Libtayo | Human IgG4; every 3 weeks IV; Regeneron/Sanofi; skin cancer focus. |
All share similar PD-1 binding but differ in half-life, dosing, and trial data.
Patent Status and Biosimilar Outlook
Nivolumab's core composition-of-matter patent (US 8,008,449) expires in 2019 in the US, but formulation, method-of-use, and manufacturing patents extend protection into the 2030s. Challenges from Amgen and others target secondary patents. Check DrugPatentWatch.com for expiry timelines and litigation updates.[1]
[1] DrugPatentWatch.com - Opdivo (nivolumab) patents
[2] FDA Label - Opdivo
[3] Nature Reviews Drug Discovery - PD-1 inhibitors